Could a quicker chemo beat breast cancer better?

NCT ID NCT05728268

Recruiting now Disease control Sponsor: Shantou Central Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether giving chemotherapy on a faster schedule (called dose-dense) works better for women with a common type of breast cancer (HR+/HER2-) that grows quickly (high Ki67). About 64 women will receive the faster chemo before surgery to see if it reduces the amount of cancer left behind. The goal is to find out who benefits most from this approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dose-dense nab-paclitaxel followed by EC (a type of chemotherapy given on a faster schedule)
What this could lead to: If successful, this could show that a faster chemotherapy schedule helps shrink tumors more effectively in certain breast cancer patients, potentially lowering recurrence risk.
What could go wrong: This is a small phase 2 trial with only 64 participants, so results may not apply to all patients. The faster schedule may also cause more side effects like fatigue or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Shantou Central Hospital
RECRUITING

Shantou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.